Nivolumab

Red

Brand Name(s):OPDIVO

Indication:Melanoma – advanced treatment in adults (unresectable or metastatic)
Non-small cell lung cancer (NSCLC) advanced or metastatic
Renal Cell Carcinoma (RCC) – advanced
Hodgkin lymphoma (relapsed or refractory classical after autologous stem cell transplant in adults).

Rationale:1,2,3

Considered:Jul-15

Review Date:Jul-22

Comments:
Drug Safety Update
Reports of organ transplant rejection
Jul-17
…………………………
NICE TA417
Nivolumab for previously treated advanced renal cell carcinoma
Nov-16
…………………………
NICE TA400
Nivolumab in combination with ipilimumab for treating advanced melanoma
July 2016
…………………………
NICE TA 384
February 2016